Evidence map›Paper›PMID 32323806›Full record

ArticleMolecular medicine reports2020

Baicalin alleviates bleomycin‑induced pulmonary fibrosis and fibroblast proliferation in rats via the PI3K/AKT signaling pathway.

Hong Zhao, Chundi Li, Lina Li, Junying Liu, Yinghui Gao, Kun Mu, Donghe Chen, Aiping Lu, Yuanyuan Ren, Zhenhua Li

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Baicalin nano-micelles for dry eye disease: LC-MS/MS method validation, pharmacokinetics and pharmacodynamics in preclinical models.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Hong ZhaoDepartment of Respiratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Chundi LiDepartment of Respiratory Medicine, Fifth Affiliated Hospital of Harbin Medical University, Daqing, Heilongjiang 163316, P.R. China.
Lina LiDepartment of Respiratory Medicine, Fifth Affiliated Hospital of Harbin Medical University, Daqing, Heilongjiang 163316, P.R. China.
Junying LiuDepartment of Respiratory Medicine, Fifth Affiliated Hospital of Harbin Medical University, Daqing, Heilongjiang 163316, P.R. China.
Yinghui GaoDepartment of Respiratory Medicine, Fifth Affiliated Hospital of Harbin Medical University, Daqing, Heilongjiang 163316, P.R. China.
Kun MuDepartment of Respiratory Medicine, Fifth Affiliated Hospital of Harbin Medical University, Daqing, Heilongjiang 163316, P.R. China.
Donghe ChenDepartment of Respiratory Medicine, Fifth Affiliated Hospital of Harbin Medical University, Daqing, Heilongjiang 163316, P.R. China.
Aiping LuDepartment of Respiratory Medicine, Fifth Affiliated Hospital of Harbin Medical University, Daqing, Heilongjiang 163316, P.R. China.
Yuanyuan RenDepartment of Respiratory Medicine, Fifth Affiliated Hospital of Harbin Medical University, Daqing, Heilongjiang 163316, P.R. China.
Zhenhua LiDepartment of Respiratory Medicine, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Harbin Medical University · CNChina Medical University · CNDaqing City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Baicalin is an important flavonoid compound THAT is isolated from the Scutellaria baicalensis Georgi Chinese herb and plays a critical role in anti‑oxidative, anti‑inflammatory, anti‑infection and anti‑tumor functions. Although baicalin can suppress the proliferation of tumor cells, the underlying mechanisms of baicalin in bleomycin (BLM)‑induced pulmonary fibrosis remain to be elucidated. Thus, the aim of the present study was to determine the role of baicalin in pulmonary fibrosis and fibroblast proliferation in rats. Hematoxylin and eosin (H&E) and Masson staining were used to measure the morphology of pulmonary fibrosis, ELIASA kits were used to test the ROS and inflammation, and western blotting and TUNEL were performed to study the apoptosis proteins. In vitro, MTT assay, flow cytometry, western blotting and immunofluorescence were performed to investigate the effects of baicalin on proliferation of fibroblasts. The most significantly fibrotic changes were identified in the lungs of model rats at day 28. Baicalin (50 mg/kg) attenuated the degree of pulmonary fibrosis, and the hydroxyproline content of the lung tissues was decreased in the baicalin group, compared with the BLM group. Further investigation revealed that baicalin significantly increased glutathione peroxidase (GSH‑px), total‑superoxide dismutase (T‑SOD) and glutathione (GSH) levels, whilst decreasing that of serum malondialdehyde (MDA). TUNEL‑positive cells were significantly decreased in rats treated with baicalin group, compared with the model group. Furthermore, it was found that BLM promoted fibroblasts viability in a dose‑dependent manner in vivo, which was restricted following treatment with different concentrations of baicalin. Moreover, BLM promoted the expression levels of cyclin A, D and E, proliferating cell nuclear antigen, phosphorylated (p)‑AKT and p‑calcium/calmodulin‑dependent protein kinase type. BLM also promoted the transition of cells from the G0/G1 phase to the G2/M and S phases, and increased the intracellular Ca2+ concentration, which was subsequently suppressed by baicalin. Collectively, the results of the present study suggested that baicalin exerted a suppressive effect on BLM‑induced pulmonary fibrosis and fibroblast proliferation.

Indexed as

AnimalsBleomycinCell Cycle CheckpointsCell ProliferationFemaleFibroblastsFlavonoidsGene Expression RegulationHydroxyprolineLungOxidative StressPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPulmonary FibrosisRatsRats, WistarbaicalinBleomycinFlavonoidsHydroxyprolinePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesSuperoxide DismutaseTransforming Growth Factor beta1apoptosisbaicalinbleomycinfibroblastoxidant stresspulmonary fibrosis

Identifiers

PMID32323806
PMCPMC7185294
OpenAlexW3014722535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.